Tripterygium Glycosides for Safely Controlling Disease Activity in Systemic Lupus Erythematosus: a Systematic Review with Meta-analysis and Trial Sequential Analysis

Overview

Journal Front Pharmacol

Date 2023 Aug 21

PMID 37601046

Authors

Yifan Chen

Liuding Wang

Nannan Li

Caiyun Zhou

Affiliations

Soon will be listed here.

Abstract

Tripterygium glycosides have been used to treat systemic lupus erythematosus (SLE) for a long time, showing the effects of immune regulation. We aimed to evaluate the benefits and risks of Tripterygium Glycosides Tablets (TGT) for patients with SLE. We searched electronic databases and clinical trial registries for relevant randomized controlled trials (RCTs). We identified eligible RCTs and assessed risk of bias. We conducted a meta-analysis to estimate the pooled effects. The Trial Sequential Analysis (TSA) 0.9.5.10 software was used to verify the reliability of the results. Eight RCTs encompassing 538 patients with SLE were included. TGT combined with conventional treatments (CTs) was superior to CTs alone in reducing lupus activity ( = -1.66, 95% = -2.07 to -1.26, < 0.00001, low-certainty evidence) and improving overall response rate (ORR) ( = 1.21, 95% = 1.11 to 1.32, < 0.0001, moderate-certainty evidence). The robustness of the results was confirmed by TSA. Regarding safety, there was no statistical difference in the overall incidence of adverse reactions between the two groups. In patients with SLE, TGT might safely reduce disease activity. However, further high-quality studies are needed to firmly establish the clinical efficacy of TGT. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022300474; Identifier: CRD42022300474.

Citing Articles

The efficacy of Tripterygium Glycosides in the treatment of Chinese patients with thyroid-associated orbitopathy: a systematic review and meta-analysis.

Li M, Wei B, Gao T, Gao C Front Pharmacol. 2025; 15():1433791.

PMID: 39834834 PMC: 11743945. DOI: 10.3389/fphar.2024.1433791.

References

Lisnevskaia L, Murphy G, Isenberg D . Systemic lupus erythematosus. Lancet. 2014; 384(9957):1878-1888. DOI: 10.1016/S0140-6736(14)60128-8. View

Zhang B, Su H, Ren X, Li W, Ding Y, Zhang X . [Study on mechanism of Cuscutae Semen flavonoids in improving reproductive damage of Tripterygium Glycosides Tablets in rats based on high-throughput transcriptome sequencing]. Zhongguo Zhong Yao Za Zhi. 2019; 44(16):3478-3485. DOI: 10.19540/j.cnki.cjcmm.20190527.402. View

Wang X, Xia Y . Anti-double Stranded DNA Antibodies: Origin, Pathogenicity, and Targeted Therapies. Front Immunol. 2019; 10:1667. PMC: 6650533. DOI: 10.3389/fimmu.2019.01667. View

Durcan L, ODwyer T, Petri M . Management strategies and future directions for systemic lupus erythematosus in adults. Lancet. 2019; 393(10188):2332-2343. DOI: 10.1016/S0140-6736(19)30237-5. View

Mak A, Cheung M, Chiew H, Liu Y, Ho R . Global trend of survival and damage of systemic lupus erythematosus: meta-analysis and meta-regression of observational studies from the 1950s to 2000s. Semin Arthritis Rheum. 2012; 41(6):830-9. DOI: 10.1016/j.semarthrit.2011.11.002. View

Li X, He Z, Ru L, Yuan Y, Yuan Z, Chen P . Efficacy and Safety of Qinghao Biejia Decoction in the Treatment of Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis. Front Pharmacol. 2021; 12:669269. PMC: 8378134. DOI: 10.3389/fphar.2021.669269. View

Wang Y, Jia L, Wu C . Triptolide inhibits the differentiation of Th17 cells and suppresses collagen-induced arthritis. Scand J Immunol. 2008; 68(4):383-90. DOI: 10.1111/j.1365-3083.2008.02147.x. View

Wang J, Wang C, Wu J, Li Y, Hu X, Wen J . Oral microemulsion based delivery system for reducing reproductive and kidney toxicity of Tripterygium glycosides. J Microencapsul. 2019; 36(6):523-534. DOI: 10.1080/02652048.2019.1631402. View

Cheng C, Wu T, Shang H, Li Y, Altman D, Moher D . CONSORT Extension for Chinese Herbal Medicine Formulas 2017: Recommendations, Explanation, and Elaboration. Ann Intern Med. 2017; 167(2):112-121. DOI: 10.7326/M16-2977. View

10.

Xu Q, Zhang X, Ge S, Xu C, Lv Y, Shuai Z . Triptoquinone A and B exercise a therapeutic effect in systemic lupus erythematosus by regulating NLRC3. PeerJ. 2023; 11:e15395. PMC: 10259444. DOI: 10.7717/peerj.15395. View

11.

Li M, Li J, Wang J, Li Y, Yang P . Serum level of anti-α-enolase antibody in untreated systemic lupus erythematosus patients correlates with 24-hour urine protein and D-dimer. Lupus. 2017; 27(1):139-142. DOI: 10.1177/0961203317721752. View

12.

Xiong S, Li Y, Xiang Y, Peng N, Shen C, Cai Y . Dysregulation of lncRNA and circRNA Expression in Mouse Testes after Exposure to Triptolide. Curr Drug Metab. 2019; 20(8):665-673. PMC: 7062010. DOI: 10.2174/1389200220666190729130020. View

13.

Sen M, Kurl A, Khosroshahi A . Pregnancy in patients with systemic lupus erythematosus after cyclophosphamide therapy. Lupus. 2021; 30(9):1509-1514. DOI: 10.1177/09612033211021163. View

14.

Dai L, Cheng C, Tian R, Ld Zhong L, Li Y, Lyu A . Standard Protocol Items for Clinical Trials with Traditional Chinese Medicine 2018: Recommendations, Explanation and Elaboration (SPIRIT-TCM Extension 2018). Chin J Integr Med. 2018; 25(1):71-79. DOI: 10.1007/s11655-018-2999-x. View

15.

Balshem H, Helfand M, Schunemann H, Oxman A, Kunz R, Brozek J . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol. 2011; 64(4):401-6. DOI: 10.1016/j.jclinepi.2010.07.015. View

16.

Ma J, Dey M, Yang H, Poulev A, Pouleva R, Dorn R . Anti-inflammatory and immunosuppressive compounds from Tripterygium wilfordii. Phytochemistry. 2007; 68(8):1172-8. DOI: 10.1016/j.phytochem.2007.02.021. View

17.

Huang C, Chen C, Chang S, Tsai G . Evaluation of Antiobesity Activity of Soybean Meal Products Fermented by FPS 2520 and N1 in Rats Fed with High-Fat Diet. J Med Food. 2020; 23(6):667-675. DOI: 10.1089/jmf.2019.4643. View

18.

Yee C, Farewell V, Isenberg D, Griffiths B, Teh L, Bruce I . The use of Systemic Lupus Erythematosus Disease Activity Index-2000 to define active disease and minimal clinically meaningful change based on data from a large cohort of systemic lupus erythematosus patients. Rheumatology (Oxford). 2011; 50(5):982-8. PMC: 3077910. DOI: 10.1093/rheumatology/keq376. View

19.

Apostolopoulos D, Morand E . It hasn't gone away: the problem of glucocorticoid use in lupus remains. Rheumatology (Oxford). 2016; 56(suppl_1):i114-i122. DOI: 10.1093/rheumatology/kew406. View

20.

Lin N, Zhang Y, Jiang Q, Liu W, Liu J, Huang Q . Clinical Practice Guideline for Glycosides/ Tablets in the Treatment of Rheumatoid Arthritis. Front Pharmacol. 2021; 11:608703. PMC: 7845140. DOI: 10.3389/fphar.2020.608703. View